Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21458928 | 0.97 | BLM (0.38) | PDK2L3MBTL1GBA1BLMPMP22 | |
| SCHEMBL21458597 | 0.97 | BLM (0.38) | PDK2L3MBTL1GBA1BLMPMP22 | |
| SCHEMBL30379736 | 0.97 | BLM (0.38) | PDK2L3MBTL1GBA1BLMPMP22 | |
| SCHEMBL21998088 | 0.90 | L3MBTL1 (0.39) | PDK2L3MBTL1GBA1CA14HDAC6 | |
| SCHEMBL23051796 | 0.86 | PDK2 (0.37) | PDK2L3MBTL1GBA1CA14HDAC6 | |
| SCHEMBL26727863 | 0.86 | CES2 (0.38) | PDK2L3MBTL1GBA1CA14HDAC6 | |
| SCHEMBL22276510 | 0.85 | PDK2 (0.40) | PDK2L3MBTL1GBA1BLMPMP22 | |
| SCHEMBL22276649 | 0.85 | PDK2 (0.40) | PDK2L3MBTL1GBA1BLMPMP22 | |
| SCHEMBL946261 | 0.83 | BLM (0.38) | PDK2L3MBTL1GBA1BLMPMP22 | |
| SCHEMBL26689402 | 0.83 | BLM (0.38) | PDK2L3MBTL1GBA1BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154152-A1 | INHIBITORS OF NAEGLERIA FOWLERI | CLEMSON UNIVERSITY | 2025-05-15 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| EP-1599471-B1 | HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS | ASTRAZENECA AB (SE) | 2008-05-28 | — | — | EP | disclosed |
| EP-1599471-B1 | HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS | ASTRAZENECA AB (SE) | 2008-05-28 | — | — | EP | disclosed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-7192974-B2 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-7192974-B2 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-7192974-B2 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-20060270637-A1 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PDK2 1509/4885L3MBTL1 1394/4885GBA1 3212/4885 |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | PDK2 2452/4885L3MBTL1 2522/4885GBA1 431/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PDK2 1509/4885L3MBTL1 1394/4885GBA1 3212/4885 |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | PDK2 1719/4885L3MBTL1 4830/4885GBA1 293/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PDK2 1509/4885L3MBTL1 1394/4885GBA1 3212/4885 |
| US-20250154152-A1 | INHIBITORS OF NAEGLERIA FOWLERI | SERPINB1, NAMPT, NIT2 | PDK2 1233/4885L3MBTL1 4765/4885GBA1 1593/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PDK2 1509/4885L3MBTL1 1394/4885GBA1 3212/4885 |
| US-20060270637-A1 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | RPS7, CYP3A7, CYP2A7 | PDK2 1570/4885L3MBTL1 1277/4885GBA1 2478/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PDK2 1509/4885L3MBTL1 1394/4885GBA1 3212/4885 |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD | PDK2 580/4885L3MBTL1 3134/4885GBA1 72/4885 |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | OPRL1, OPRD1, OPRK1 | PDK2 774/4885L3MBTL1 4651/4885GBA1 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.